Related Experiment Video
Updated: May 12, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
International validation of the low anterior resection syndrome score
Therese Juul1, Madelene Ahlberg, Sebastiano Biondo
1*Department of Surgery P, Aarhus University Hospital, Aarhus, Denmark †General and Digestive Surgery, Colorectal Unit, Bellvitge University Hospital, Barcelona, Spain ‡Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden §Hospital Valle de Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain ‖Department of Surgery, University Erlangen, Erlangen, Germany.
Objective:
The aims of this study were to investigate the convergent and discriminative validity and reliability of the low anterior resection syndrome (LARS) score in an international setting.
Background:
The LARS score is a simple self-administered questionnaire measuring bowel dysfunction after rectal cancer surgery. The score is intended to be commonly used in international research and clinical practice in the future. Therefore, a thorough validation in an international setting is of utmost importance.
Methods:
The LARS score was translated using methods in keeping with current international recommendations. A total of 801 patients operated for rectal cancer in Sweden, Spain, Germany, and Denmark completed the LARS score questionnaire, including an anchor question assessing the impact of bowel function on quality of life. A subgroup of 218 patients completed the LARS score twice. Data were analyzed per country.
Results:
The LARS score has demonstrated a high convergent validity in terms of a high correlation between LARS score and quality of life (P < 0.001). Sensitivity ranged from 67.7% to 88.3% and specificity from 58.1% to 86.3%. The LARS score was able to discriminate between groups of patients differing with regard to radiotherapy, surgery, and age (P < 0.05). The score also demonstrated high reliability at test-retest with narrow limits of agreement and no statistically significant difference between scores at the first and second test.
Conclusions:
The Swedish, Spanish, German, and Danish versions of the LARS score have proven to be valid and reliable tools for measuring LARS in European rectal cancer patients.
